Show Summary Details
Page of

The Pharmacokinetics and Clinical Therapeutics of the Antiepileptic Drugs 

The Pharmacokinetics and Clinical Therapeutics of the Antiepileptic Drugs
Chapter:
The Pharmacokinetics and Clinical Therapeutics of the Antiepileptic Drugs
Author(s):

Mark Cook

and Simon Shorvon

DOI:
10.1093/med/9780199659043.003.0026
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2022. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 25 May 2022

There are 23 first and second antiepileptic drugs in current usage, 15 of which were licensed since 1989. An understanding of their pharmacokinetics and pharmacology is important for clinical therapeutics. In this chapter the following anti epileptic drugs are considered: carbamazepine, clobazam, clonazepam, eslicarbazepine, ethosuxumide, felbamate, gabapentin, lacosamide, lamotrigine, leveracetam, phenobarbital, phenytoin, primidone, oxcarbazepine, pregabalin, retigabine, rufinamide, stiripentol, tiagabine, topiramate, valproate, vigabatrin, and zonisamide. Brief details are provided of: history of drug introduction, mechanism of action, pharmacokinetic properties, drug interactions, side effects, effectiveness, indications, preparations, dosage and blood level monitoring. The information is given in a concise form to assist physicians in their clinical practice.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.